Naprod Life Sciences has renewed its Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Tarapur manufacturing facility, reaffirming continued access to Brazil and other regulated Latin American markets.
The renewal follows a successful regulatory inspection conducted in July 2025, covering the company’s oncology injectable and oral solid dosage operations. The partner-led audit involved a detailed evaluation of manufacturing processes, quality systems and regulatory compliance, and was completed without any critical observations.
Naprod’s Tarapur facility is an integrated manufacturing site with dedicated oncology and general blocks, equipped to produce liquid and lyophilised injectable formulations as well as oral solid dosage forms. The renewed certification allows the company to continue manufacturing and supplying oncology and select general therapeutic products to Brazil, the largest pharmaceutical market in Latin America.
The ANVISA approval further strengthens Naprod’s global regulatory footprint, which includes EU-GMP, PIC/S and WHO-GMP certifications. As Brazil is a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), the certification also supports access to other PIC/S-aligned markets across the region.
The renewed certification aligns with Naprod’s growth strategy by enabling product commercialisation, expanding its international customer base, and supporting partnerships in contract manufacturing, co-development and technology transfer, thereby improving speed-to-market across key global markets.
Also Read